Table 3.

Resource utilisation in the ITT patient group

	Pre-omalizumab (n=218)	Post-omalizumab (n=218)	Mean difference (95% CI)
A&E visits/patient	1.12 (1.71)	0.37 (0.91)	−0.75 (−0.99 to −0.52), p<0.001
Inpatient admissions/patient	1.24 (1.64)	0.56 (1.33)	−0.68 (−0.85 to −0.51), p<0.001
Outpatient visits/patient*	4.60 (2.48)	1.60 (2.07)	−3.00 (−3.43 to −2.58), p<0.001
Bed days/patient	6.61 (9.73)	3.39 (8.49)	−3.22 (−4.31 to −2.12), p<0.001
Day case visits/patient	0.03 (0.18)	0.03 (0.19)	0.00 (−0.04 to 0.03), p>0.01

Data are presented as mean (SD).

*Excluding visits for omalizumab administration.

ITT: intention to treat.